key: cord-0827372-1a7ugd24
authors: Tappe, B.; Lauruschkat, C. D.; Strobel, L.; Pantaleon Garcia, J.; Kurzai, O.; Rebhan, S.; Kraus, S.; Pfeuffer-Jovic, E.; Bussemer, L.; Possler, L.; Held, M.; Huenniger, K.; Kniemeyer, O.; Schaeuble, S.; Brakhage, A.; Panagiotou, G.; White, L. P.; Einsele, H.; Loeffler, J.; Wurster, S.
title: COVID-19 patients share common, corticosteroid-independent features of impaired host immunity to pathogenic molds
date: 2022-04-22
journal: nan
DOI: 10.1101/2022.04.21.22274082
sha: 0908d12b138bde69465b6d14ce37a6564ccc5520
doc_id: 827372
cord_uid: 1a7ugd24

Patients suffering from coronavirus disease-2019 (COVID-19) are at high risk for deadly secondary fungal infections such as COVID-19-associated pulmonary aspergillosis (CAPA) and COVID-19-associated mucormycosis (CAM). Despite this clinical observation, direct experimental evidence for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-driven alterations of antifungal immunity is scarce. Using an ex-vivo whole blood (WB) stimulation assay, we challenged blood from twelve COVID 19 patients with Aspergillus fumigatus and Rhizopus arrhizus antigens and studied the expression of activation, maturation, and exhaustion markers, as well as cytokine secretion. Compared to healthy controls, T-helper cells from COVID-19 patients displayed increased expression levels of the exhaustion marker PD-1 and weakened A. fumigatus- and R. arrhizus-induced activation. While baseline secretion of proinflammatory cytokines was massively elevated, WB from COVID-19 patients elicited diminished release of T-cellular (e.g., IFN-{gamma}, IL-2) and innate immune cell-derived (e.g., CXCL9, CXCL10) cytokines in response to A. fumigatus and R. arrhizus antigens. Additionally, samples from COVID-19 patients showed deficient granulocyte activation by mold antigens and reduced fungal killing capacity of neutrophils. These features of weakened anti-mold immune responses were largely decoupled from COVID-19 severity, the time elapsed since diagnosis of COVID-19, and recent corticosteroid uptake, suggesting that impaired anti-mold defense is a common denominator of the underlying SARS-CoV-2 infection. Taken together, these results expand our understanding of the immune predisposition to post-viral mold infections and could inform future studies of immunotherapeutic strategies to prevent and treat fungal superinfections in COVID-19 patients.

Patients suffering from coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are highly susceptible to fungal superinfections, especially COVID-19-associated pulmonary aspergillosis (CAPA) and COVID-19-associated mucormycosis (CAM) [1, 2] . CAPA has been encountered in approximately 15% of COVID-19 patients admitted to the intensive care unit (ICU), with regional high incidence rates of up to 39%, depending on classification criteria and diagnostic strategy [1, 3] . Similarly, devastating regional outbreaks of CAM considerably aggravated the death toll of COVID-19 and its burden on healthcare systems, especially during the spring 2021 wave of COVID-19 in India [2] . Deeper knowledge of the immunological factors driving the predisposition to CAPA and CAM will be essential to guide improved strategies for the prevention, targeted diagnosis, and treatment of these deadly coinfections.

Current hypotheses regarding the emergence of CAPA and CAM involve a combination of virusinduced damage of airway epithelia, severe immune dysregulation with impaired cellular immunity and exuberant hyperinflammatory cytokine release, and predisposing host factors such as structural lung diseases or poorly controlled diabetes mellitus [2] [3] [4] [5] [6] [7] [8] . These intrinsic risk factors are further compounded by iatrogenic immunosuppression (glucocorticosteroids [GCS] and/or monoclonal antibodies) and disruption of the microbiome by broad-spectrum antibiotics [2] [3] [4] [5] [6] [7] [8] . While the clinical risk factors predisposing COVID-19 patients to mold infections have been studied [2, 6] , experimental evidence for impairment of anti-mold immunity resulting from the underlying viral infection is scarce.

Instead, most of the presumed immunopathological mechanisms underlying the predisposition to CAPA and CAM were either extrapolated from other viral/fungal co-infections such as influenzaassociated pulmonary aspergillosis (IAPA) or from global changes to the immune landscape in COVID-19 patients [9] . Furthermore, while the vastly different epidemiology of CAPA and CAM has been linked to underlying host factors (e.g., the high number of patients with unknown or uncontrolled diabetes mellitus in India) [6, 10, 11] , and, possibly, environmental exposures [10] , little is known about similarities or differences in SARS-CoV-2-driven impairment of immune responses to Aspergillus and Mucorales.

Venous blood was collected using the Monovette ® blood collection system (Sarstedt, Nürnbrecht, Germany). Lithium-heparin-and hirudin-anticoagulated blood was used for whole blood (WB)-based immunoassays. Polymorphonuclear cells (PMNs) were isolated from EDTA-anticoagulated blood. All blood samples were processed within 2 h of collection.

A protein extract from an Aspergillus fumigatus mycelial lysate (AfuLy) was obtained as described previously [13] . A Rhizopus arrhizus lysate (RarLy) was obtained from an in-house clinical isolate 

A. fumigatus strain American Type Culture Collection (ATCC) 46645 was plated on beer wort agar (Oxoid, Wesel, Germany) and incubated at 30 °C for 4 days. The plate was rinsed with sterile distilled water to harvest the conidia and the conidial suspension was passed through a 20-µm cell strainer (Miltenyi Biotec, Bergisch Gladbach, Germany). To generate A. fumigatus germlings (AfuG), RPMI medium (20 mL in 50-mL tubes) was inoculated with 2×10 7 conidia. Tubes were incubated at 25 °C and 200 rpm until germlings reached a length of 10-30 µm. After centrifugation at 5000×g for 10 min, germlings were resuspended in RPMI medium at 1×10 6 AfuG/mL. (Rar-2021-10) was plated on beer wort agar and incubated at 30 °C for 6 days. Spores were harvested as described above. R. arrhizus germlings (RarG, length 20-40 µm) were generated at 37 °C in RPMI medium without shaking.

To analyze adaptive immunity and cytokine release, ex-vivo WB stimulation was performed in 2.7-mL Monovette ® tubes, as previously described [13] . Briefly, tubes without anticoagulants were prepared with antigenic stimuli (AfuLy, RarLy, and/or SARS-CoV-2 Protein S [PrS, Miltenyi Biotec, Bergisch Gladbach, Germany]), co-stimulatory antibodies (α-CD28 and α -CD49d, Miltenyi Biotec, Bergisch Gladbach, Germany), and RPMI medium, as summarized in Table S1 . Phytohemagglutinin (Roche, Basel, Switzerland) without co-stimulatory antibodies was used as a positive control. Tubes were cryopreserved at -20 °C for up to 4 weeks. Tubes were thawed, kept at 37 °C for at least 30 min prior to blood injection, and thoroughly disinfected with ethanol. Five-hundred microliters of heparinized WB was injected with an insulin syringe. Tubes were then incubated for 24 h at 37 °C. For flow cytometric analyses, brefeldin A (10 µg/mL, Sigma-Aldrich St.Louis, MO, USA) was added after 4 h of incubation.

For innate immune cell stimulation, a modified WB stimulation approach was used [14] . Tubes were prepared as described above and as summarized in Table S1 . Differences compared to WB stimulation for adaptive immunoassays were i) omission of co-stimulatory antibodies, ii) the use of germlings (AfuG, RarG) instead of lysates, iii) the use of hirudin-anticoagulated WB instead of heparinized WB, and iv) a shorter incubation period of 4 h at 37 °C.

Multiplex cytokine assays WB was stimulated as described above. Tubes were centrifuged at 2000×g for 20 min. Plasma was collected, aliquoted, and cryopreserved at -80 °C until further analysis. Cytokine and chemokine concentrations were measured using the Cytokine Human Magnetic 35-Plex Panel (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions. Acquisition was performed using a Luminex detection system (Bio-Plex 200 system) and Bio-Plex Manager™ Software 6.2 (Bio-Rad, Hercules, CA, USA).

For the analysis of innate immunity and baseline characterization of leukocyte distributions, WB samples were centrifuged for 5 min at 2000×g at room temperature (RT). Cells were resuspended in 500 µL HBSS and aliquoted for different antibody panels. Antibodies for extracellular staining were added as detailed in Table S2 , along with the fixable Viobility TM Live/Dead Dye (Miltenyi Biotec, Bergisch Gladbach, Germany) and dihydrorhodamine 123 (Sigma-Aldrich, St. Louis, MO, USA) for visualization of reactive oxygen species (ROS). After incubation in the dark for 20 min at RT, erythrocyte lysis buffer (EL buffer, Qiagen Inc., Venlo, Netherlands) was added. Tubes were incubated for 2 min (with repeated inversion) and centrifuged at 5000×g for 5 min. Supernatants were discarded and the erythrocyte lysis step was repeated. Cells were washed with 1 mL HBSS, For flow cytometric assessment of T cells, WB was processed and stained as described before [13] .

Antibody panels are summarized in Table S2 . Samples were acquired on a Cytoflex AS34240 flow cytometer (Beckman Coulter, Brea, CA, USA).

Downstream data analysis was performed with Kaluza v.2.1 (Beckman Coulter, Brea, CA, USA).

Gating strategies and representative raw data are shown in Figure S1 and S2 (adaptive immunity panels) and Figure S3 (innate immunity panels).

Fungicidal activity of polymorphonuclear cells All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. After incubation, wells were washed twice with 1 mL of ice-cold water for hypotonic lysis of PMNs (5 min incubation period per wash step). Hyphae were resuspended in 100 µL prewarmed RPMI + 10% FCS. Two-hundred microliters of prewarmed HBSS supplemented with 400 µg/mL of 2,3-bis-(2methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanilide (XTT, Alfa Aesar, Thermo Fisher Scientific, Waltham, MA, USA) and 50 µg/mL of 2,3-dimethoxy-5-methyl-p-benzoquinone-coenzyme (Sigma-Aldrich, St. Louis, MO, USA) were added. After 45 min of incubation at 37 °C, triplicates of 100 µL supernatant were transferred to a 96-well plate and OD 450 was measured in a microplate reader (Tecan, Maennerdorf, Switzerland). Fungal XTT metabolism was calculated according to the following formula:

Data compilation, statistical analyses, and visualization were performed using Microsoft Excel and GraphPad Prism v.9 (GraphPad Software, San Diego, CA, USA). Median-to-median ratio (MMR) was used as a descriptive surrogate of effect sizes between patients and controls. The 2-tailed Mann-All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. were used for correlation analyses. Principal component analysis (PCA) of cytokine profiles was performed with ClustVis (https://biit.cs.ut.ee/clustvis/) [15] based on ln(x)+1-transformed data.

Signatures of baseline and antigen-induced expression levels of activation/maturation/exhaustion markers and logarithmically-transformed cytokine concentrations were analyzed using QIAGEN IPA core analysis (digitalinsights.quiagen.com, Qiagen Inc., Venlo, Netherlands) [16] to determine canonical pathway enrichment. Mean-based expression ratios between COVID-19 patients and controls were compared against the gene and chemical Ingenuity Knowledge Base modules, considering all confidence levels to identify direct and indirect relationships. Enrichments of canonical pathways were considered significant at an absolute z-score value within the past 7 days, totaling to 0-280 mg prednisolone equivalent (median 120 mg).

None of the patients was neutropenic at the time of immune cell sampling and only 2 out of the 12 patients had lymphocytopenia (defined as an absolute lymphocyte count < 1000/μL). Medians for leukocyte, neutrophil, and lymphocyte counts were 8000/μL, 5470/μL, and 1170/μL, respectively. Creactive protein (CRP) values of 8 patients exceeded the normal range (0-5 mg/L) and five patients showed strongly elevated CRP (>10 mg/L). Median CRP was 8.46 mg/L.

The patient cohort had a more granulocyte-prone leukocyte distribution than control subjects (median 40.3% vs. 25.2%), with a trend toward lower relative T-cell portions among viable leukocytes (median 22.7% vs. 41.7%) and significantly lower natural killer (NK)-cell frequencies (median 1.4% vs. 5.5%, p = 0.019, Figure 1B) . However, the median absolute NK-cell count (147/μL) in COVID-19 patients was well within the normal range and only two patients had NK-cell counts below 50/μL.

lymphocytes were normal and comparable between patients and controls ( Figure 1C ). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Effector/memory phenotypes of Th cells and CTLs were similar in patients and controls, except for a shift from effector memory cells toward an effector/T EMRA phenotype among CD8 bright CTLs (p = 0.005, Figure 1D ) in COVID-19 patients, which is expectable during or after an acute viral infection [17, 18] . Th polarization was comparable in both cohorts, with type-1 Th cells (Th1) being the predominant phenotype (43% in controls, 40% in patients, Figure 1D ). Although most patients had signs of acute inflammation (CRP, leukocytosis), these data suggest that COVID-19 patients and controls enrolled in this study had largely comparable baseline features of T-cell immunity.

In order to evaluate cellular activation and cytokine release in response to A. fumigatus antigens, we used a previously established WB-based stimulation system (Figure 2A ) [13, 19] . Stimulation conditions were pre-optimized for each cell type ( Figure 2B ). Background-adjusted antigen-induced responses were defined as the difference between antigen-reactive response and unstimulated background (Figure 2A) . For flow cytometric markers with high baseline expression (>25% of the cell population of interest), we additionally compared fold changes of mean fluorescence intensity (MFI).

With regard to CD154 expression, the best-characterized flow cytometric marker for comprehensive mold-reactive Th-cell quantification [20, 21] and surrogate of recent and long-term mold exposure [22, 23] , the patient cohort had lower background-corrected AfuLy-induced T-cell frequencies (median 0.05%) than controls (median 0.10%, Figure 2C ). However, this trend was non-significant (p = 0.086) and both cohorts had generally rather low frequencies of CD154-responsive Th cells, suggesting that the results of the subsequent assays were not confounded by significant differences in prior mold encounters (e.g., through occupational exposures). In contrast, patients had significantly lower CD69 + background-corrected AfuLy-responsive T-cell frequencies than controls (median 0.04% vs. 0.15%, p = 0.002, Figure 2C) , suggesting a potential deficit in Th activation. Memory/effector phenotypes and polarization of CD154 + AfuLy-reactive cells were comparable among patients and controls, with a predominance of central memory cells and Th1 cells ( Figure 2D ). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Next, we quantified a set of 35 cytokines and chemokines to analyze the AfuLy-induced cytokine release in WB samples from COVID-19 patients and controls. PCA plots suggested increasing segregation of the two cohorts from unstimulated background to AfuLy-reactive responses to background-corrected AfuLy-induced responses ( Figure 3A ). The latter comparison showed almost complete separation of 95% confidence areas between patients and controls, with one notable outlier in the patient cohort (highlighted with a # in Figures 3A and B) . Figure 3B) . T-cellular cytokines, including surrogates of Th1 (e.g., IFN-γ, IL-2) and Th2

(IL-4, IL-5, IL-13) activation, accounted for most of the significantly disparate responses. Considering All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101/2022.04.21.22274082 doi: medRxiv preprint the etiology of differential background-corrected AfuLy-induced release, that is, elevated unstimulated background ( Figure S4 ) versus genuinely impaired AfuLy-reactive responses, a subset of four cytokines (IFN-γ, IL-2, IP-10/CXCL10, MIG/CXCL9) showed both significantly reduced AfuLyreactive and background-corrected AfuLy-induced responses ( Figure 3C , red asterisks in Figure 3B , individual concentrations shown in Figure 3D ). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ;

Dectin-1 (MMR 0.62, Figure S6B ). In contrast, we found no differences in AfuG-induced DC activation between patients and controls, except for a non-significant trend toward weaker upregulation of the maturation marker CD83 in patient samples (MMR 0.54, Figure 4A ).

Unlike the deficient T-cellular cytokine responses, impaired granulocyte responses were partially reproducible when WB from healthy donors underwent concomitant stimulation with AfuG and PrS.

While PrS induced slight activation of granulocytes from most healthy donors, dual challenge with AfuG + PrS weakened the fungus-induced response compared to AfuG alone (e.g., median ratio in fold changes of ROS MFI 0.49, p = 0.039, Figure 4C ). However, changes in marker expression after dual antigen challenge versus AfuG alone were considerably weaker compared to differences between COVID-19 patients and controls. This observation suggests that both underlying in-vivo alterations (e.g., exhaustion) and immune attenuation during dual antigen exposure contribute to the observed post-COVID-19 granulocyte dysfunction.

Given the impaired granulocyte activation and ROS response, we hypothesized that neutrophils from COVID-19 patients might elicit less potent fungicidal activity. Testing this hypothesis in a metabolic fungal killing assay, we found stronger XTT metabolism by A. fumigatus germlings after coculture with PMNs from patients versus controls at all 3 E:T ratios tested (MMR 1.59-1.91, p = 0.029 at E:T 0.5, Figure 4D ). Taken together, these findings indicate that granulocytes from COVID-19 patients have weakened reactivity to A. fumigatus antigens and impaired fungicidal activity.

Impact of causative SARS-CoV-2 variant and clinical characteristics on surrogates of anti-Aspergillus immunity In view of the known differences in host-pathogen interactions between different SARS-CoV-2 variants [26, 27], we performed univariate correlation analysis to test whether the causative viral variants disparately impacted immune responses to A. fumigatus. Background-corrected AfuLyinduced cytokine response was largely unaffected by the causative viral mutant (Figure S7A-B) .

However, there was a global trend toward more pronounced baseline hypercytokinemia in Delta patients (e.g., ρ > 0.8 for IL-4, IL-7, and IL-2R, Figure S7A-B) . This trend also persisted in nonbackground-corrected AfuLy-reactive responses (Figure S7A-B) .

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. For A. fumigatus-induced activation of antigen-presenting cells (APCs), we found a modest trend toward weaker reactogenicity to the fungus in Delta versus Alpha patients (e.g., ρ = -0.41 for ROS MFI, Figure S7C ). This trend even reached significance when comparing individual backgroundadjusted frequencies of AfuG-reactive ROS-and CD62L-positive granulocytes (both p = 0.028, Figure S7D ). Expectedly, increasing COVID-19 severity had a modest negative effect on most surrogates of innate immune cell activation and maturation, most notably on CD83 upregulation (ρ = -0.53, Figure S8D ).

Aligning with trends for cytokine responses, innate immune cell activation and maturation mostly worsened with increasing time post COVID-19 infection ( Figure S8D) . Interestingly, most surrogates of innate immune cell responsiveness, especially percentages of granulocytes producing ROS in All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101/2022.04.21.22274082 doi: medRxiv preprint response to AfuG, showed modest to strong improvement with increasing GCS uptake (ρ = 0.72, p = 0.011, Figure S8D -E). Of note, Dectin-1 is known to be suppressed after DC activation by A.

fumigatus antigens [28]; therefore, inverse correlation trends support the conclusions regarding innate immune cell activation for all 3 studied clinical parameters.

Taken together, these data suggest that the observed alterations in anti-Aspergillus immune responses are conserved across the heterogenous patient cohort. Immune dysfunction was largely unaffected by the studied clinical characteristics, except for greater impairment of granulocyte function in patients during the Delta wave and an association of GCS uptake with improved baseline hypercytokinemia and restored granulocyte dysfunction.

Inspired by the emerging reports of CAM [2] , we additionally tested anti-Mucoralean immunity in patients during the Delta wave. To that end, we selected R. arrhizus, the most common causative Mucorales species in patients with CAM [2] . As was the case for AfuLy stimulation, frequencies of background-corrected CD154 + RarLy-reactive Th cells (median 0.13% vs. 0.09%, Figure S9A Twenty out of the 35 tested background-corrected RarLy-induced cytokine responses were significantly weaker in COVID-19 patients than in controls, including most of the studied T-cellular cytokines and a number of APC-derived cytokines (Figure 5A) . PCA identified two distinct clusters formed by RarLy-induced cytokine responses in patient and control samples, with non-overlapping 95% confidence areas (Figure 5B) . Although baseline hypercytokinemia in unstimulated samples All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In order to extrapolate an overall model of antifungal immune impairment in COVID-19 patients, we performed pathway enrichment analysis. As evident from the raw data, unsupervised enrichment analysis confirmed both exuberant baseline inflammation and increased T-cellular exhaustion in unstimulated samples of COVID-19 patients (Figure 6A) . Furthermore, enrichment analysis confirmed broad impairment of all major background-adjusted Th responses to A. fumigatus and R.

arrhizus antigens, with overall more diminished enrichment for responses to R. arrhizus (Figure 6A ).

Based on trends in cytokine responses and flow cytometric markers, enrichment analysis further predicted signals of weakened immune cell activation via PRR signaling and impaired crosstalk of All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101/2022.04.21.22274082 doi: medRxiv preprint various leukocyte populations (e.g., NK-cell/DC crosstalk) in mold-stimulated blood samples from COVID-19 patients (Figure 6A) .

Altogether, our results support a model whereby baseline hypercytokinemia, signals of immune exhaustion, reduced reactogenicity of innate immune cells (especially granulocytes), impaired cytokine responses to mold antigens, and potential disruption of intercellular feedback loops, contribute to less potent antifungal immunity in COVID-19 patients (Figure 6B ). Potentially synergizing with other infection-and therapy-related effects on post-COVID-19 host defense and additional underlying risk factors, these severe immune alterations likely contribute to the predisposition of patients with and after COVID-19 to invasive mold infections ( Figure 6B ).

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Although various risk factors for secondary fungal infections in COVID-19 patients have been described [2, 6, 10] , direct experimental evidence for alterations of antifungal immunity has been

lacking. Yet, identification of immunopathogenic links between the viral infection and predisposition to fungal co-infections will be essential to guide the development and use of immunomodulatory drugs in the treatment of post-viral mold infections. Herein, we identified three major mechanisms of diminished immune responses to two major mold pathogens, A. fumigatus and R. arrhizus, in COVID- In addition to cytokine/chemokine-mediated lung injury, hyperinflammation can adversely shape the systemic immune environment [9] . For instance, it has been hypothesized that the susceptibility to fungal pathogens is partially linked to dysregulated interferon signaling [9] . Sustained production of high levels of type I interferons (i.e., IFN-α/β) can result in lymphopenia, weakened Th-cell activation, All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. the APC cytokine IP10/CXCL10, which was less potently secreted in response to mold antigens in our patient cohort, is a strong chemoattractant for T cells, monocytes, and NK cells [37] . Given the use of a WB-based assay instead of isolated cell populations for most assays shown in this manuscript, such feedback loops were captured by our approach [13] and enrichment analysis further corroborated signs of impaired crosstalk between key APC and Th populations ( Figure 6A ). Importantly, our study specifically focused on direct post-COVID-19 impedance of mold antigenreactive immunity in an ex-vivo setting. Therefore, our approach was not designed to investigate other, partially pre-described features of impaired antifungal defense in COVID-19 patients, such as pulmonary pathophysiology (discussed above), the role of endothelial inflammation, or the systemic in-vivo impact of iatrogenic interventions. Consequently, our findings only cover a small yet potentially impactful portion of the complex co-pathogenesis of COVID-19 and opportunistic mold infections ( Figure 6B) . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Due to the restrictive exclusion criteria, a major limitation of this study was the relatively small cohort size, especially for responses to R. arrhizus that were only tested during the Delta wave (after the emergence of CAM). The high consistency of our findings, among a heterogenous patient cohort, All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101/2022.04.21.22274082 doi: medRxiv preprint

COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From Immunology to Treatment

The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. The Lancet. Microbe

A Visual and Comprehensive Review on COVID-19-Associated Pulmonary Aspergillosis (CAPA)

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Co-infections: potentially lethal and unexplored in COVID-19

COVID-19 associated pulmonary aspergillosis

Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19

COVID-19-associated invasive pulmonary aspergillosis

Pathogenesis of Respiratory Viral and Fungal Coinfections

Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World

Characteristics of undiagnosed diabetes in men and women under the age of 50 years in the Indian subcontinent: the National Family Health Survey

A minimal common outcome measure set for COVID-19 clinical research

Development of a Simple and Robust Whole Blood Assay with Dual Co-Stimulation to Quantify the Release of T-Cellular Signature Cytokines in Response to Aspergillus fumigatus Antigens

A Virtual Infection Model Quantifies Innate Effector Mechanisms and Candida albicans Immune Escape in Human Blood

ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap

Causal analysis approaches in Ingenuity Pathway Analysis

Plasticity in programming of effector and memory CD8+ Tcell formation

Diversity in T Cell Memory: An Embarrassment of Riches

Development and evaluation of a whole blood-based approach for flow cytometric quantification of CD154+ mould-reactive T cells

Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity

The authors wish to thank all blood donors. This work was supported by a grant of the "Stiftung zur Förderung der Krebsforschung an der Universität Würzburg ("Forschung hilft")", grant allocation number 8607630 (to CDL and JL); "Nachweis von Immunzellbotenstoffen gegen Covid-19 für die Diagnostik und Impfstofftestung". The study was further supported by the Deutsche Forschungsgemeinschaft (DFG) within the Collaborative